Hans Lee is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
335 24th Ave N Ste 200
Nashville, TN 372031516
Telephone
615-284-2310Provider last certified this registry record 27 Feb 2026.
Clinical trials
- A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: SCRI Development Innovations, LLC
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Sponsor: National Cancer Institute (NCI)
- Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
40 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20256 payments$18,591openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20254 payments
- Menarini Silicon Biosystems, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
64.7%Thalidomide Analog61%Revlimid42%Lenalidomide35%Pomalyst23%Part D≥31 patientsBCL-2 Inhibitor1.9%Venclexta100%Part D<11 patients+ 1 more class in this area
Anti-infectives
17.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.2%Valacyclovir100%Part D≥39 patientsShort-acting sulfonamides3.2%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
9.5%Proton pump inhibitor5.2%Pantoprazole Sodium100%Part D≥23 patientsSerotonin-3 Receptor Antagonist4.3%Ondansetron Hcl100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”